Michael Levine
Cardiovascular Disease · New Milford, CTNPI 1982676862
Payments from drug & device makers
Across 10 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$51
- Abbott$45
- Neurocrine Biosciences, Inc.$44
- Amgen$37
- E.r. Squibb & Sons, L.L.C.$15
- Boston Scientific$13
What the payments were for
- Food & beverage$204100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 2 | $51 |
| Abbott | 2 | $45 |
| Neurocrine Biosciences, Inc. | 2 | $44 |
| Amgen | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Boston Scientific | 1 | $13 |
How this compares
$204 in reported general payments places this provider in the 15th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 638 | $804,545 |
| XareltoRivaroxaban | 238 | $301,600 |
| EntrestoSacubitril/Valsartan | 37 | $47,895 |
| Repatha SureclickEvolocumab | 40 | $46,520 |
| BrilintaTicagrelor | 24 | $26,383 |
| Metoprolol Succinate | 598 | $8,836 |
| Atorvastatin Calcium | 605 | $7,105 |
| Losartan Potassium | 389 | $3,507 |
| Ezetimibe | 147 | $3,303 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 99 | $3,219 |
| Digoxin | 105 | $2,909 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 22 | $2,706 |
| Furosemide | 374 | $2,657 |
| Metoprolol Tartrate | 350 | $2,626 |
| Amlodipine Besylate | 332 | $2,322 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New Milford
- Harlan KrumholzNew Haven$4M
- Jeffery TestaniNew Haven$3.4M
- Nihar DesaiNew Haven$3.2M
- Stuart ZarichBridgeport$1.3M
- John ForrestNew Haven$1.2M
- Hyung ChunNew Haven$1.1M
- Rohan KheraNew Haven$930K
- Brett NowlanBloomfield$798K
- Carlos Mena-HurtadoNew Haven$665K
- Raymond McKayHartford$636K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.